Movers: Intel, Time Warner, Alcoa, Monsanto, Satyam

(page 2 of 2)

, its cable franchise rights) in fourth quarter 2008 of about $15 billion. In addition, TWC says it anticipates incurring a noncash pretax impairment charge of about $350 million related to its investment in Clearwire Corp. As a result of these charges, TWC now expects to incur a net loss and a loss per diluted share in 2008.

Ingersoll-Rand (IR) says the U.S. Department of Energy (DOE) has selected IR's Trane unit, a global provider of indoor comfort systems and comprehensive facility solutions, for an Indefinite Delivery Indefinite Quantity (IDIQ) Energy Savings Performance Contract (ESPC) worth up to $5 billion. Work may extend through 2019 if the government elects to exercise all contract options, IR noted.

Perry Ellis International (PERY) sees lwoer-than-expected fourth quarter revenue of $200-$210 million, EPS of about breakeven. Cites retail partners requesting later deliveries of goods, significant increase in markdowns and sales allowances for holiday season, deceleration in sales at department and specialty store channels, primarily for luxury brands, reduction of private label replenishment bottoms business, weakness in international markets. Sees fiscal year 2009 EPS of $0.55-$0.65 on revenue of $860-$870 million.

Ethan Allen Interiors (ETH) says it plans to consolidate operations of its Eldred, PA, upholstery manufacturing plant and several of its retail service centers. About $8-$9 million of pre-tax restructuring, impairment and other related charges are expected to be taken in the second half of fiscal year 2009.

Microchip Technology (MCHP) expects third quarter sales to be down 29%-31% sequentially, with non-GAAP EPS of $0.23-$0.26.

Constellation Brands (STZ) posts $0.60, vs. $0.55, third quarter non-GAAP EPS as lower interest expense offset 6% reported sales decline. Tightens fiscal year 2009 EPS guidance to a range of $1.68-$1.72 from previous estimate of $1.68-$1.76.

Standard Microsystems (SMSC) posts $0.39, vs. $0.53, third quarter non-GAAP EPS on 20% sales decline, narrowed operating margins. Cites prolonged troubles in the global economy and a major inventory correction in the PC market. Sees fourth quarter sales of $45-$51 million, non-GAAP loss of $0.40-$0.55.

La Jolla Pharmaceutical (LJPC) and Biomarin (BMRN) announce agreement to develop, commercialize Riquent, LJPC's investigational drug for lupus nephritis, in U.S., Europe and all other territories of the world, excl. Asia Pacific region. Following a successful Phase 3 trial, the companies will share equally in all losses and profits. Under terms of agreement, BMRN will receive a company-exclusive license to develop and commercialize Riquent and LJPC could receive up to $289 million in cash through milestones and equity purchases by BMRN.